Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2019 May;8(5):259-272.
doi: 10.1002/psp4.12381. Epub 2019 Mar 22.

Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network

Lourdes Cucurull-Sanchez  1 , Michael J Chappell  2 , Vijayalakshmi Chelliah  3 , S Y Amy Cheung  4   5 , Gianne Derks  6 , Mark Penney  7 , Alex Phipps  8 , Rahuman S Malik-Sheriff  9 , Jon Timmis  10 , Marcus J Tindall  11   12 , Piet H van der Graaf  3   13 , Paolo Vicini  14   15 , James W T Yates  16
Affiliations

Best Practices to Maximize the Use and Reuse of Quantitative and Systems Pharmacology Models: Recommendations From the United Kingdom Quantitative and Systems Pharmacology Network

Lourdes Cucurull-Sanchez et al. CPT Pharmacometrics Syst Pharmacol. 2019 May.

Abstract

The lack of standardization in the way that quantitative and systems pharmacology (QSP) models are developed, tested, and documented hinders their reproducibility, reusability, and expansion or reduction to alternative contexts. This in turn undermines the potential impact of QSP in academic, industrial, and regulatory frameworks. This article presents a minimum set of recommendations from the UK Quantitative and Systems Pharmacology Network (UK QSP Network) to guide QSP practitioners seeking to maximize their impact, and stakeholders considering the use of QSP models in their environment.

PubMed Disclaimer

Conflict of interest statement

L.C.‐S. is an employee and shareholder of GlaxoSmithKline. S.Y.A.C. is an employee of AstraZeneca. M.P. is an employee and shareholder in Union Chimique Belge. A.P. is an employee and shareholder of Hoffmann‐La Roche. J.T. is Director of SimOmics Ltd. As Editor‐in‐Chief of CPT: Pharmacometrics & Systems Pharmacology, P.H.v.G. was not involved in the review or decision process for this article. P.V. is an employee of MedImmune, a wholly owned subsidiary of AstraZeneca. J.W.T.Y. is an employee and shareholder of AstraZeneca. M.J.C., V.C., G.D., R.S.M.‐S. and M.J.T. have no conflicts of interest to declare.

Figures

Figure 1
Figure 1
Annual number of PubMed abstracts containing the term “systems pharmacology” since the year 2000.
Figure 2
Figure 2
Example of good practice in model structure visualization.
See this image and copyright information in PMC

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Allerheiligen, S.R. Next‐generation model‐based drug discovery and development: quantitative and systems pharmacology. Clin. Pharmacol. Ther. 88, 135–137 (2010). - PubMed
    1. News & Analysis . News in brief. Nat. Rev. Drug Discovery 10, 889 (2011).
    1. van der Graaf, P.H. CPT: Pharmacometrics and systems pharmacology. CPT Pharmacometrics Syst. Pharmacol. 1, e8 (2012). - PMC - PubMed
    1. Chelliah, V. et al BioModels: ten‐year anniversary. Nucleic Acids Res. 43, D542‐D548 (2015). - PMC - PubMed
    1. Lloyd, C.M. et al The CellML model repository. Bioinformatics 24, 2122–2123 (2008). - PubMed

Publication types

Substances